„Moderna“ akcijos krenta nepaisant vakcinų pardavimų daugiau nei tris kartus, palyginti su praėjusiais metais

TOPLINE

Shares of Moderna dropped on Wednesday even after the biotech company reported higher-than-expected revenue and profits in the first quarter, with results boosted by soaring coronavirus vaccine sales which more than tripled from a year ago.

svarbiausi faktai

Moderna’s stock fell roughly 1.5% to around $144 per share on Wednesday despite the vaccine-maker ataskaitų first quarter earnings that beat Wall Street expectations, as revenue and profits surged from a year ago.

Shares initially jumped by as much as 5% in pre-market trading following the strong earnings results, before giving up gains later in the morning.

Moderna’s quarterly revenue came in at more than $6 billion—compared to the $4.6 billion expected by Wall Street analysts, while net income of nearly $3.7 billion more than tripled from the first quarter of 2021.

The company reported $5.9 billion in coronavirus vaccine sales during the first quarter, a more than threefold increase from the $1.7 billion in sales a year ago.

Moderna predicts $21 billion in total vaccine sales for 2022, with a boost in the second half of the year thanks to increased vaccination campaigns in the fall season, management said.

The company expects to receive regulatory approval for a redesigned vaccine that targets the omicron variant by this summer and its coronavirus vaccines for children will be reviewed by the Food and Drug Administration in June.

Svarbi citata:

“The virus is mutating to become more and more infectious, and there’s waning immunity,” CEO Stephane Bancel sakė, CNBC on Wednesday. “It is going to be really important to boost people in the fall with a better adapted vaccine which is what we’re working towards.”

Stebinantis faktas:

Moderna shares are down roughly 38% so far this year, amid a wider market sell-off that has been driven by large declines in technology and healthcare stocks.

Ką žiūrėti:

Moderna’s cash pile grew to $19.3 billion by the end of the first quarter, a notable increase from $17.6 billion in December 2021. Bancel hinted at possible M&A activity during Moderna’s earnings call, saying that the company “will not be shy to invest” in new opportunities. “I can tell you our teams have never been as busy,” he said, adding, “they are looking at a lot of opportunities literally across the world.”

Didelis skaičius: 4.8 milijardas dolerių

That’s how much Moderna CEO Stephane Bancel is vertasPagal "Forbes"’ calculations. He has held the top job at the biotech company since 2011 and holds a roughly 8% stake.

Papildoma literatūra:

„Moderna“ akcijų žlugimas: nuostoliai viršija 140 milijardų dolerių, nes viešai neatskleista informacija parduoda milijonus dolerių akcijomis ("Forbes")

Rinkos coliais aukštesnės, tačiau ekspertai perspėja apie „nuolatinį nepastovumą“ po „žiauraus“ akcijų išpardavimo ("Forbes")